Sponsor: National Cancer Institute
LIvES Study: Lifestyle Intervention for oVarian cancer Enhanced Survival The CRCPHP in partnership with the Arizona Cancer Center and the national Gynecological Oncology Group of the National Cancer Institute has launched the first comprehensive study to investigate the role of a healthy diet and physical activity behavioral intervention on ovarian cancer survival. One in 71 women will be diagnosed with ovarian cancer in their lifetime. Survival continues to be less than optimal and efforts to improve survival through healthy lifestyle have yet to be evaluated. This study will recruit over 1000 ovarian cancer survivors from across the country for a 2-year intervention. Study participants receive important health information to promote study engagement and healthy behavior change. The coaching is delivered via Internet using a new interactive coaching platform developed by the UA Arizona Research Laboratories at the BIO5 Institute. UA students from the College of Public Health and Nutritional Sciences undergo an extensive training program offered by center staff lead, Tracy Crane, a registered dietitian who coordinates this national study. With partnerships it is amazing what can be accomplished!.
Principal Investigator:Marcia Stefanick (PI, Stanford University)
Cynthia Thomson (Arizona Site PI)
Amelia Lobos (Study Coordinator)
The study started in 1993 to evaluate health outcomes in aging postmenopausal women and to identify factors associated with healthy aging. Between 1993 and 1998, more than 161,000 women between 50 and 79 years of age joined the WHI. Beginning in October 2004, participants were consented for the WHI Extension Study (ES). The ES follow-up entailed an annual mailing to obtain self-reported outcomes, hormone use among HT trial participants, and quality of life. Other data collection included a one-time collection of historical diagnoses of Parkinson’s disease and diabetes (ES Year 1) , and medication and supplement use (ES Year 5). Throughout the initial extension period, participants previously randomized to the intervention arm of the Dietary Modification trial received a quarterly newsletter to promote maintenance of the dietary behaviors taught by the intervention. To assess dietary intake during this period, random sample of DM participants completed a 24-hour dietary recall in ES Years 1 and 5.
Evaluation of Diindolylmethane Supplementation to Modulate Tamoxifen Efficacy in Breast Cancer: The Diindolylmethane (DIM) Efficacy Study
Principal Investigator: Cynthia Thomson, PhD, RD, CSO
Co-Investigators: Alison Stopeck, MD (Medical Oncologist, Stony Brook University) Patricia Thompson, PhD (Professor COPH, Stony Brook University) Denise Roe, PhD (Biostatistician COPH, member UACC) Sherry Chow, PhD (Associate professor- Pharmacology, member UACC)
Sponsor: National Cancer Institute
To date, no prospective, randomized, placebo-controlled clinical trials have been conducted to test the hypothesis that exposure to diindolylmethane (DIM), in combination with tamoxifen (TAM), can significantly modify breast cancer risk. The DIME Study tests the novel hypothesis that DIM will demonstrate an enhanced efficacy of TAM by modulating the breast parenchyma to a ‘low’ density, ‘low risk’ state and alternatively by favorably modulating steroid hormone metabolism. In fact, DIM has been shown to act on breast cancer risk through a variety of mechanisms, and as such, core breast biopsy tissue samples and blood for alternate hypotheses testing (e.g., COX-2, prolactin receptor, proliferation assays, AhR, inflammatory markers, oxidative stress, etc) are collected in the context of this trial. The recruitment portion of the study ended in September 2015. Study results will be available late 2015 to early 2016.